Lilly's Oral Weight Loss Pill Maintains Results After Injectables

Eli Lilly's (LLY) orforglipron oral pill successfully maintained weight loss in patients switching from injectable GLP-1 drugs, offering a more convenient obesity treatment option with FDA decision expected early 2026.